DSIP vs Dihexa
Both DSIP and Dihexa are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
DSIP
Evidence CDelta Sleep-Inducing Peptide
A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.
View full DSIP profile →Dihexa
Evidence CDihexa (PNB-0408)
An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.
View full Dihexa profile →Side-by-Side
| Attribute | DSIP | Dihexa |
|---|---|---|
| Evidence Grade | C | C |
| FDA Status | Not FDA-approved — research compound | Not FDA-approved — research compound (HGF/c-Met-mimetic) |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 8–45 mg orally daily (research-only) |
| Clinics Indexed | 38 | 10 |
| Categories | sleep, neuroprotection | cognitive, neuroprotection |
Key reported benefits — DSIP
- ✓Slow-wave-sleep signals (preclinical)
- ✓Stress/cortisol modulation
- ✓Possible analgesic effect
Key reported benefits — Dihexa
- ✓Synaptogenesis (preclinical)
- ✓Memory improvement (animal)
- ✓Possible Alzheimer's relevance
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.